



# Closing Remarks

January 29, 2016



# GCIIG: Then and Now





Cervix Cancer Education Symposium, January 2017, Mexico City

	Radiotherapy utilisation rate (%)	Mean radiotherapy fractions per course	5-year local control benefit (%)	5-year overall survival benefit (%)
Breast	87	16	15	2
Cervix	71	21	35	20
Colorectal	19	23	5	2
Haematological	48	8	7	4
Head and neck	74	22	34	20
Liver	0	0	0	0
Lung	77	16	9	6
Oesophagus	71	15	5	2
Prostate	58	28	25*	1
Stomach	27	19	2	1
Total	50	18	10	4

Radiotherapy utilisation rate is the number of patients for whom radiotherapy is the treatment of choice according to guidelines and evidence, divided by the number of new cases in one year. Haematological cancers include leukaemia, Hodgkin's lymphoma, non-Hodgkin lymphoma, and multiple myeloma. \*5-year biochemical disease-free survival for curative cases only.

**Table 1: Radiotherapy utilisation rate, mean fractions, and outcome benefits (absolute proportional) for top ten cancers globally by incidence**

# CCRN: Significant Issues

- Money (Funding Sources)
- Per case reimbursement?
- Accrual
- Ongoing oversight (QA and FU)
- Insurance/Indemnity issues
- Site Selection
- Infrastructure (clinical trials management)

# CCRN: Current Support

- Funding Sources (on going)
  - IGCS
  - GCIG
- This meeting supported by:
  - Elekta
  - Varian
  - Advaxis
  - Stendahl
  - Zeria

# CCRN: Potential Sources of Support

- IGCS (current support)
- GCIG (current support)
- Center for Global Health, NIH, USA
- Gates Foundation and other Foundations
- ASCO grants
- Industry (Elekta/Varian/Pharma)
- CCRN Society (Dues)
- Grants (eg ASCO and others)
- Charitable Organizations
- Social Media
- Advocacy Groups

# CCRN: Thanks!

- Our Hosts
- Funding for this meeting
  - Elekta
  - Varian
  - Advaxis
  - Stendahl
  - Zeria
- Funding for CCRN
  - GCIG
  - IGCS
- All of you
- And, Monica, of course!